Deal of the Week: Pfizer Sticks It to U.S. Treasury

Each week, host Alex Sherman, a Bloomberg mergers and acquisitions reporter, is joined by a colleague to discuss the most interesting and market-moving M&A news. 


In this episode, Alex and Global M&A Managing Editor McCracken discuss the largest deal of the year and the biggest health care deal ever, Pfizer Inc. and Allergan Plc's $160 billion merger. They ponder whether the deal, constructed so that Pfizer will pay lower taxes by domiciling in Ireland, opens the door for more so-called inversions just as the U.S. Treasury tries to crack down on them.

Frank Aquila, a partner at Sullivan & Cromwell, joins Alex and Jeff to compare M&A in the 1980s with the present day, crediting companies and their advisers for doing smarter deals now, while regretting one particular merger that never got done.

Before it's here, it's on the Bloomberg Terminal.